Immunogenicity of melanoma-associated gangliosides in cancer patients - PubMed (original) (raw)
Immunogenicity of melanoma-associated gangliosides in cancer patients
T Tai et al. Int J Cancer. 1985.
Abstract
The immunogenicity of gangliosides found on human melanoma cells was determined from sera of 26 melanoma patients who were immunized every 1-4 weeks for 4 months with tumor-cell vaccine (TCV) prepared from cultured melanoma cells. Total lipid-bound sialic acid in the gangliosides isolated from TCV was 0.38 mumol/10(8) cells, and was distributed as follows: 44.8% to GM3, 44.2% to GD3, 5.6% to GM2, and 4.6% to GD2. Sera were tested at monthly intervals for antibodies to each ganglioside by ELISA with purified gangliosides as the antigen source. The immunologic specificity of the antibody was confirmed by absorption tests. None of the 26 patients had detectable anti-GM3, anti-GD3, or anti-GD2 antibodies before immunization, although anti-GM2 antibody was detected in 3 patients. After immunization, 2 patients developed IgM anti-GD2, 10 developed IgM anti-GM2, and 2 developed IgG anti-GM2 antibodies. No patient developed detectable anti-GM3 or anti-GD3 antibodies. These results indicate that both GD2 and GM2 expressed on human melanoma cells are immunogenic in humans, although GM2 appears to be more immunogenic. The other two gangliosides, GM3 and GD3, are present in human sera and in human normal tissues, and thus immunologic tolerance may have been established against these gangliosides. Alternatively, circulating GM3 and GD3 may have neutralized anti-GM3 and anti-GD3 antibodies, if any were induced by TCV immunization.
Similar articles
- Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Ragupathi G, et al. Int J Cancer. 2000 Mar 1;85(5):659-66. doi: 10.1002/(sici)1097-0215(20000301)85:5<659::aid-ijc11>3.0.co;2-5. Int J Cancer. 2000. PMID: 10699946 Clinical Trial. - Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ. Kitamura K, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2805-9. doi: 10.1073/pnas.92.7.2805. Proc Natl Acad Sci U S A. 1995. PMID: 7708728 Free PMC article. - IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.
Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. Takahashi T, et al. J Invest Dermatol. 1999 Feb;112(2):205-9. doi: 10.1046/j.1523-1747.1999.00493.x. J Invest Dermatol. 1999. PMID: 9989797 - Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO. Livingston PO. Immunol Rev. 1995 Jun;145:147-66. doi: 10.1111/j.1600-065x.1995.tb00080.x. Immunol Rev. 1995. PMID: 7590824 Review. - Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P. Hersey P. Cancer Treat Res. 1991;54:137-51. doi: 10.1007/978-1-4615-3938-4_8. Cancer Treat Res. 1991. PMID: 1673856 Review.
Cited by
- Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis.
Ramos RI, Bustos MA, Wu J, Jones P, Chang SC, Kiyohara E, Tran K, Zhang X, Stern SL, Izraely S, Sagi-Assif O, Witz IP, Davies MA, Mills GB, Kelly DF, Irie RF, Hoon DSB. Ramos RI, et al. Mol Oncol. 2020 Aug;14(8):1760-1778. doi: 10.1002/1878-0261.12702. Epub 2020 Jun 5. Mol Oncol. 2020. PMID: 32358995 Free PMC article. - Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins.
Xia L, Schrump DS, Gildersleeve JC. Xia L, et al. Cell Chem Biol. 2016 Dec 22;23(12):1515-1525. doi: 10.1016/j.chembiol.2016.10.012. Epub 2016 Nov 23. Cell Chem Biol. 2016. PMID: 27889407 Free PMC article. - Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.
Vázquez AM, Rodrèguez-Zhurbenko N, López AM. Vázquez AM, et al. Front Oncol. 2012 Nov 20;2:170. doi: 10.3389/fonc.2012.00170. eCollection 2012. Front Oncol. 2012. PMID: 23181219 Free PMC article. - A conjugate of an oligosaccharide fragment of tumor-associated ganglioside antigen with hemocyanin is a prototype antitumor vaccine.
Stepanenko RN, Tsvetkov YE, Khatuntseva EA, L'vov VL, Vlasenko RY, Nifant'ev NE, Petrov RV. Stepanenko RN, et al. Dokl Biol Sci. 2007 Jul-Aug;415:298-301. doi: 10.1134/s001249660704014x. Dokl Biol Sci. 2007. PMID: 17929671 No abstract available. - Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.
Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Gerlini G, et al. Am J Pathol. 2004 Dec;165(6):1853-63. doi: 10.1016/S0002-9440(10)63238-5. Am J Pathol. 2004. PMID: 15579430 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical